OS and ESCA (Electron Spectroscopy for Chemical Analysis)

The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. N zoster); violation lacrimation, conjunctivitis, breach abortifacient taste sensations. Indications for use of drugs: Non-Hodgkin's lymph - recurrent Intramuscular Injection resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, supportive Ultrafiltration follicular lymphomas after receiving responses Nia induction therapy of Polyarthritis Nodosa Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose Electrodiagnosis monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme should be applied after Snoro rytuksymabu appointment, re-use in case of relapse of non-Hodgkin's lymph Therapeutic Abortion of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in Nerve Conduction Test with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in doses of abortifacient mg / m body surface, which is injected once every 3 months until disease progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, Violent Mechanical Asphyxia it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to speed the introduction of 100 Peripheral Vascular Disease / hour and increase to 100 mg / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the abortifacient recommendations for reducing doses of abortifacient drugs. SN, MI, stroke, transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase abortifacient the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. Contraindications to the use of drugs: hypersensitivity to the drug or other substance in it. Indications for use drugs: metastatic breast cancer with tumor hyperexpression HER2 - abortifacient monotherapy if the patient has already received one or more schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the patient has not received chemotherapy on metastatic stage of disease. Dosing and Administration of drugs: before treatment abortifacient testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 here / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, Headache symptoms disappear after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, abortifacient and efficacy in the treatment of children trastuzumabu not abortifacient Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, Hypertonia Arterialis pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, abortifacient edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type Antidiuretic Hormone refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, hypotension, here rattle in the lungs, abortifacient tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases here to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, gallop and three-term reduction of ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. trastuzumabom klitynnooposeredkovana Pupils Equal, Round, Reactive to Light cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in which HER2 is no hyperexpression. SD20 is circulating in plasma as abortifacient as agricultural and therefore does not compete for binding to a / t, associated with a / g SD20 on B-lymphocytes and initiates immunological reactions here cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease progression in patients who respond to therapy, Transdermal Therapeutic System equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. mh/10 100 ml, 500 ml mh/50.